Pear’s apps guide users through behavioral therapy. Pear Therapeutics, which has three FDA-cleared prescription apps to help treat substance use disorder and insomnia, filed for bankruptcy on ...

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, today provides an update on significant progress in its ...

Less than two years after Pear Therapeutics went public in a SPAC deal worth $1.6 billion, its assets were sold in an auction for just $6 million.

Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy. PursueCare, which bought some of Pear’s assets, is relaunching apps for treating substance use disorders.

But its revenue numbers still show a challenge in getting therapeutics to patients. By the end of 2021, Pear expects to bring in just $4 million in revenue, according to an investor presentation ...

Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick ...

Pear Therapeutics said Tuesday that it will become a publicly traded company through a merger with a special purpose acquisition company, or SPAC. The deal values the combined company at about $1. ...

Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp. announced today that the U.S ...

Pear Therapeutics said it would grow from $4 million in 2021 to a whopping $125 million by the end of 2023. ... Pear filed for bankruptcy and announced it would lay off almost all of its employees.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines ...

Pear Therapeutics, Inc. (“Pear”) has built the first end-to-end platform for prescription digital therapeutics (PDTs), which are FDA-authorized, clinician-prescribed, and payor-reimbursed ...